王蓓,王淅,吕晓皑

• 1:浙江省中医院乳腺病中心
• 2:上海交通大学医学院

摘要(Abstract)：

目的分析吉西他滨联合顺铂(GP方案)治疗复发转移性三阴乳腺癌的反应率及不良反应,进一步了解该方案治疗可获取的疾病进展时间(TTP)和总生存时间(OS)。方法回顾性分析住院治疗的35例晚期三阴乳腺癌。所有患者均一线接受GC方案(吉西他滨针1 000 mg/m2,d1、d8+顺铂针25 mg/m2,d1-3,每21天重复)化疗。患者每2周期接受疗效评价。统计肿瘤反应率和不良反应,通过后续随访,统计TTP和OS。结果 35例晚期三阴乳腺癌,均有可评价病灶。21例继往接受了含紫杉类药物辅助化疗,14例患者继往接受了含蒽环类药辅助化疗。入组后患者共接受2～6周期GP方案化疗,中位数为3.8周期。完全缓解(CR)2例(5.7%),部分缓解(PR)10例(28.6%),疾病稳定(SD)6例(17.1%),疾病进展(PD)7例(20.0%),总反应率(ORR)为34.3%。中位TTP为7.0月,中位OS为13.0月。结论晚期三阴乳腺癌接受GP方案化疗有较高反应率,耐受性好,但TTP较短,生存时间有限,需要寻找更为有效的治疗靶点。

关键词(KeyWords)： 乳腺肿瘤/药物疗法;吉西他滨/治疗应用;顺铂/治疗应用;回顾性研究

Abstract:

Keywords:

基金项目(Foundation): 浙江省卫生厅基金(2010KYA149)

作者(Author): 王蓓,王淅,吕晓皑

DOI: 10.13267/j.cnki.syzlzz.2011.05.005

参考文献(References)：

• [1]Reis-Filho JS,Tutt AN.Triple negative tumours:acritical review[J].Histopathology,2008,52(1):108-118.
• [2]王蓓,傅健飞,吕晓皑.74例三阴乳腺癌的特征及治疗进展[J].实用肿瘤杂志,2011,26(1):95-98.
• [3]唐上宜,彭小丹,沈虹,等.吉西他滨联合长春瑞滨治疗蒽环类和紫杉类耐药的晚期乳腺癌疗效和安全性评价[J].实用肿瘤杂志,2010,25(3):308-310.
• [4]Eisenhauer EA,Therasse P,Bogaerts J,et al.Newresponse evaluation criteria in solid tumours:revisedRECIST guideline(version 1.1)[J].Eur J Cancer,2009,45(2):228-247.
• [5]Allred DC,Harvey JM,Berardo M,et al.Prognostic andpredictive factors in breast cancer byimmunohistochemical analysis[J].Mod Pathol,1998,11(2):155-168.
• [6]Wolff AC,Hammond ME,Schwartz JN,et al.AmericanSociety of Clinical Oncology/College of AmericanPathologists guideline recommendations for humanepidermal growth factor receptor 2 testing in breast cancer[J].J Clin Oncol2,0072,5(1):118-145.
• [7]Petrelli F,Cabiddu M,Ghilardi M,et al.Current data oftargeted therapies for the treatment of triple-negativeadvanced breast cancer:empiricism or evidence-based[J]?Expert Opin Investig Drugs,2009,18(10):1467-1477.
• [8]Sirohi B,Arnedos M,Popat S,et al.Platinum-basedchemotherapy in triple-negative breast cancer[J].AnnOncol,2008,19(11):1847-1852.
• [9]Maisano R,Zavettieri M,Azzarello D,et al.Carboplatinand gemcitabine combination in metastatic triple-negativeanthracycline-and taxane-pretreated breast cancerpatients:A phaseⅡstudy[J].J Chemother,2011,23(1):40-43.
• [10]Koshy N,Quispe D,Shi R,et al.Cisplatin-gemcitabinetherapy in metastatic breast cancer:Improved outcome intriple negative breast cancer patients compared to non-triple negative patients[J].Breast,2010,19(3):246-248.
• [11]Thomas ES,Gomez HL,Li RK,et al.Ixabepilone pluscapecitabine for metastatic breast cancer progressingafter anthracycline and taxane treatment[J].J ClinOncol,2007,25(33):5210-5217.